Fairvalue-Calculator Fairvalue-Calculator
EN DE

One Glove Group (5079) Fair Value & Analysis

Healthcare · MY · Market cap 78.7M MYR

Price0.1400 MYR
Fair Value0.1400 MYR
Upside+0.0%
Quality92/100
Evidence: Low Range 0.1100 MYR – 0.2100 MYR

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

One Glove Group (5079) currently trades at 0.1400 MYR, while our model-based Fair Value estimate is 0.1400 MYR — implying the stock looks roughly 0.0% undervalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

One Glove Group Berhad, an investment holding company, manufactures, markets, and sells examination gloves and other related activities in Malaysia, Japan, Germany, the United States, India, and internationally. The company offers powder-free nitrile butadiene rubber medical examination and industrial gloves. It also sells fresh fruit bunches. The company was formerly known as GETS Global Berhad and changed its name to One Glove Group Berhad in July 2022. One Glove Group Berhad was incorporated in 2002 and is based in Kamunting, Malaysia.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is One Glove Group (5079) undervalued?
As of Jun 26, 2026, our model estimates a fair value of 0.1400 MYR versus a price of 0.1400 MYR — about +0% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 5079?
Our 21-model fair value for One Glove Group is 0.1400 MYR (as of Jun 26, 2026), built from audited fundamentals. The current price is 0.1400 MYR.
What is the quality score of 5079?
One Glove Group has a Quality Score of 92/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.